1、全部翻完 Thymic Squamous Cell Carcinomas 作为关键词的 19 页结果。差不多是 case 居多，还有症状，自己看看吧，应该已包含全部有该完整关键词的文章！可能有 漏，觉得不够你也可以自己翻。不过建议不要浪费时间再翻，可以搜其他关键词。祝 你研究顺利 Alles Gute. 看到我眼睛痛！ p.s 每篇上面的是链接，不过我都是全部复制过来，建议如果你觉得这个作者说的有 道理可以点开查看相关介绍的链接。如果觉得差不多就不用每个点开了。希望能帮到 你！加油！ 晚期的多峰性治疗胸腺癌 link: http:/www.ncbi.nlm.nih.gov/pubmed/253
2、11849 Gen Thorac Cardiovasc Surg. 2015 Mar;63(3):159-63. doi: 10.1007/s11748-014-0486-7. Epub 2014 Oct 14. Multimodality treatment for advanced thymic carcinoma: outcomes of induction therapy followed by surgical resection in 16 cases at a single institution. Shintani Y1, Inoue M, Kawamura T, Funaki
3、 S, Minami M, Okumura M. Author information 1Department of General Thoracic Surgery, Osaka University Graduate School of Medicine, 2-2-L5 Yamadaoka, Suita, Osaka, 565-0871, Japan, yshintanithoracic.med.osaka-u.ac.jp. Abstract OBJECTIVE: We reviewed our institutional experience with cases of multimod
4、ality treatment for advanced thymic carcinoma to determine patient outcomes and prognostic indicators. METHODS: Between 1998 and 2014, 16 patients with a Masaoka stage III or IV thymic carcinomaunderwent surgical resection after induction therapy at Osaka University Hospital. These were considered t
5、o have great vessel invasion or metastasis to the mediastinal or intrathoracic lymph nodes based on the preoperative workup findings, and received induction therapy. RESULTS: Complete tumor resection was achieved in 11 (69 %) after the induction therapy. Pathological findings revealed that 10 patien
6、ts had Masaoka stage III disease, 1 had IVa, and 5 had IVb. The histological diagnosis was squamous cell carcinoma in 13, neuroendocrine carcinoma in 2, and undifferentiated carcinoma in 1. The 5-year survival rate for all patients was 71 %. Survival was significantly better in patients who underwen
7、t a complete resection (R0 disease) as compared to those with incompletely resected tumors (R1 or R2 disease). CONCLUSIONS: Multimodality treatment offers encouraging results and complete resection provides high survival rate for patients with advanced thymic carcinoma. link: http:/www.ncbi.nlm.nih.
8、gov/pubmed/25629460 Long-Term Outcomes of Surgery for Thymic Carcinoma: Experience of 25 Cases at a Single Institution. Tagawa T1, Suzuki H1, Nakajima T1, Iwata T1, Mizobuchi T1, Yoshida S1, Yoshino I1. Author information Abstract Background Thymic carcinoma, a relatively rare entity, often presents
9、 as locally advanced disease, and sometimes as distant metastatic disease. The treatment strategy, long-term surgical outcomes and clinical prognostic factors have yet to be fully elucidated. Methods Clinical charts of 25 patients who underwent surgery for thymic carcinoma at our institution from 19
10、91 to 2014 were retrospectively reviewed. Results The Masaoka stage was stage I in three patients (12%), II in eight (32%), III in four (16%), IVa in four (16%), and IVb in six (24%). Histologic subtypes weresquamous cell carcinoma in 12 patients, well-differentiated neuroendocrine carcinoma in 5, u
11、ndifferentiated carcinoma in 3, adenocarcinoma in 1, and others in 4. Three patients had paraneoplastic syndrome including myasthenia gravis, multiple endocrine neoplasia type 1 (MEN1), and Cushing syndrome. Neoadjuvant chemotherapy was administered to five patients (20%). Complete resection was ach
12、ieved in 17 patients (68%). There were no perioperative deaths. Twelve patients received postoperative therapy. The 5- and 10-year overall survival rates were 76.2 and 63.5%, respectively. The 5- and 10-year survival rates of patients with Masaoka stage I- III were 88.9 and 74.1%, respectively, wher
13、eas the 5-year survival rate of stage IV was 50.0%. The 5- and 10-year survival rates of 17 patients who underwent complete resection were 88.9 and 71.1%, respectively. Of the 17 patients with complete resection, 3 patients experienced recurrence including lung and supraclavicular lymph node. Conclu
14、sion Even for this highly malignant disease, surgery could contribute to favorable long-term outcomes in the setting of multimodality therapy. Georg Thieme Verlag KG Stuttgart New York. link: http:/www.ncbi.nlm.nih.gov/pubmed/24427739 Anti-Apoptotic Signature in Thymic Squamous Cell Carcinomas - Fun
15、ctional Relevance of Anti-Apoptotic BIRC3 Expression in the ThymicCarcinoma Cell Line 1889c. Huang B1, Belharazem D2, Li L3, Kneitz S1, Schnabel PA4, Rieker RJ4, Krner D5, Nix W6, Schalke B7,Mller-Hermelink HK1, Ott G8, Rosenwald A1, Strbel P3, Marx A2. Author information Abstract The molecular path
16、ogenesis of thymomas and thymic carcinomas (TCs) is poorly understood and results of adjuvant therapy are unsatisfactory in case of metastatic disease and tumor recurrence. For these clinical settings, novel therapeutic strategies are urgently needed. Recently, limited sequencing efforts revealed th
17、at a broad spectrum of genes that play key roles in various common cancers are rarely affected in thymomas and TCs, suggesting that other oncogenic principles might be important. This made us re-analyze historic expression data obtained in a spectrum of thymomas and thymicsquamous cell carcinomas (T
18、SCCs) with a custom-made cDNA microarray. By cluster analysis, different anti-apoptotic signatures were detected in type B3 thymoma and TSCC, including overexpression of BIRC3 in TSCCs. This was confirmed by qRT-PCR in the original and an independent validation set of tumors. In contrast to several
19、other cancer cell lines, the BIRC3-positive TSCC cell line, 1889c showed spontaneous apoptosis after BIRC3 knock-down. Targeting apoptosis genes is worth testing as therapeutic principle in TSCC. KEYWORDS: MTCH2; apoptosis; gene expression; myasthenia gravis; targeted therapy; thymic carcinoma; thym
20、oma; thymus link: http:/www.ncbi.nlm.nih.gov/pubmed/23866799 Surgical treatment and prognosis of thymic squamous cell carcinoma: a retrospective analysis of 105 cases. Zhao Y1, Zhao H, Hu D, Fan L, Shi J, Fang W. Author information Abstract BACKGROUND: Thymic squamous cell carcinomas are rare malign
21、ancies with limited information regarding results of surgery therapy. The objective of the current study was to evaluate their clinical and pathologic features and possible prognostic factors. METHODS: From February 2003 to December 2010, 105 consecutive surgical patients were enrolled in this study
22、 with pathologic confirmed thymic squamous cell carcinoma in Shanghai Chest Hospital. Clinical and pathologic data were retrospectively reviewed. Survival analysis was performed using the Kaplan-Meier and log rank tests. Multivariate analysis was performed using the Cox regression model. RESULTS: Th
23、e squamous cell subtype made up 73.4% of the thymic carcinomas and 16.1% of totalthymic tumors. Four patients (3.8%) presented with myasthenia gravis. The 5-year overall survival rate and the disease-free survival rate were 59.5% and 57.6%, respectively. On multivariate analysis, only the completene
24、ss of resection (hazard ratio 3.692; 95% confidence interval: 1.827 to 7.464; p=0.001) was found to have significant impact on overall survival. Completeness of resection (hazard ratio 2.361; 95% confidence interval: 1.226 to 4.547; p=0.010) and chemotherapy (hazard ratio 0.307; 95% confidence inter
25、val: 0.134 to 0.704; p=0.005) were associated with disease-free survival. CONCLUSIONS: Complete resection not only predicts better overall survival but also extends disease-free interval after resection of thymic squamous cell carcinoma. Our results provide additional evidence supporting an alternat
26、ive clinical stage specific for thymic carcinoma. Copyright 2013 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved. link: http:/www.ncbi.nlm.nih.gov/pubmed/23639785 Identification of novel mutations of TP53, ALK and RET gene in metastatic thymic squamous cell carcinoma
27、 and its therapeutic implication. Hu Z1, Wang J, Yao T, Hong RL, Zhang K, Gao H, Wu X, Li J, Bai C, Yen Y. Author information Abstract Thymic tumors are epithelial tumors of the thymus for which multimodal therapies are often ineffective because of a lack of standardized regimens. Due to the low inc
28、idence, the molecular pathology and genomic abnormalities of thymic epithelial tumors are largely unknown. In this study, we report our comprehensively genomic study on a case of metastatic thymic tumor. Using next generation deep DNA sequencing technology, we sequenced 190 segments of 46 cancer gen
29、es of the cancer genome to cover 739 COSMIC mutations in 604 loci. Among these sequenced cancer genes, we identified that three low frequency (10% of cells) mutations in the TP53 gene (c.782+1GT), ALK gene (c.3551CT), and RET gene (c.2651AT). To the best of our knowledge, this is the first study to
30、show those mutations in thymic tumor. Of note, our study further indicates comprehensive molecular analysis may facilitate development of novel diagnostic and therapeutic strategies for thymic tumors. Copyright 2013 Elsevier Ireland Ltd. All rights reserved. link: http:/www.ncbi.nlm.nih.gov/pubmed/2
31、0714951 Thymic squamous cell carcinoma with multiple brain metastases. Yang JT1, Chang CM, Lee MH, Chen YJ, Lee KF. Author information Abstract Thymic carcinomas are rare epithelial malignancies with marked invasive tendency which can metastasize to distant organs, most commonly to the lung, bone, l
32、iver, kidney and extra-thoracic lymph nodes. Central nervous system metastasis is extremely rare and only 45 such cases have been reported in the English literature. We reported a 42-year-old male with thymic squamous cell carcinoma and lung and bones metastases. He underwent thymomectomy and pulmon
33、ary lobectomy with concurrent chemo-radiotherapy. Based on the clinical symptoms of severe headache and vomiting and the results of brain computed tomography and magnetic resonance imaging scans, 2 metastatic tumors with a cystic component were diagnosed. We resected the metastatic tumors and the si
34、gns of increased intracranial pressure subsided immediately after the operation. The patient underwent continuous chemotherapy systemically and whole brain irradiation for disease control. This presentation suggests that surgical resection with concurrent chemo-radiotherapy is the treatment of choic
35、e for thymic carcinomas with brain metastases. link: http:/www.ncbi.nlm.nih.gov/pubmed/19967491 Thymic squamous cell carcinoma producing granulocyte colony-stimulating factor associated with a high serum level of interleukin 6. Ayabe E1, Kaira K, Takahashi T, Murakami H, Tsuya A, Nakamura Y, Naito T
36、, Endo M, Yamamoto N. Author information Erratum in Int J Clin Oncol. 2010 Feb;15(1):116. Abstract Granulocyte colony-stimulating factor (G-CSF)-producing thymic carcinoma is extremely rare. A- 66-year-old man presented with an anterior mediastinal mass, and underwent surgical biopsy. He had marked
37、leukocytosis, and his serum levels of G-CSF and interleukin-6 were elevated. Histologically, the tumor consisted of squamous cell carcinoma, which showed positive immunoreactivity for G-CSF. He was treated with thoracic radiotherapy, and chest imaging revealed a marked reduction of tumor size. He wa
38、s doing well at 8 months after tumor diagnosis. link: http:/www.ncbi.nlm.nih.gov/pubmed/15283186 Thymic squamous cell carcinoma producing parathyroid hormone-related protein and CYFRA 21-1. Yoshiike F1, Koizumi T, Yoneyama A, Komatu M, Yamaguchi S, Hanaoka M, Kubo K, Eda S. Author information Abstra
39、ct A 54-year-old man was admitted to our hospital because of dyspnea. Radiographic examination showed an anterior mediastinal mass and pericardial effusion. Serum calcium and parathyroid hormone-related protein (PTHrP) levels were elevated, and serum CYFRA 21-1 level was extremely high. Results of p
40、ercutaneous needle biopsy under computed tomography guidance led to a diagnosis of moderately differentiated squamous cell carcinoma. Immunohistological staining showed the tumor cells to be positive for PTHrP and cytokeratin monoclonal antibodies. Postmortem findings were considered to indicate thy
41、mic carcinoma. Thymic carcinoma is rare, but our case indicates that thymicsquamous cell carcinoma can be identified in terms of paraneoplastic hypercalcemia. http:/www.ncbi.nlm.nih.gov/pubmed/7773875 Squamous cell carcinoma of the thymus with paraneoplastic hypercalcemia.与上同 Negron-Soto JM1, Cascad
42、e PN. Author information Abstract Primary thymic carcinoma is a rare neoplasm that in contradistinction to thymoma, is not supposed to be associated with a paraneoplastic syndrome. A 73-year-old man, with new onset of disorientation, was found to have an elevated serum calcium level as the cause. Co
43、mputed tomography demonstrated a mediastinal mass, pericardial invasion, and metastases to the lung. Examination of a biopsy specimen revealed thymic squamous cell carcinoma. Thus, a paraneoplastic syndrome, in this case hypercalcemia, does not exclude primary carcinoma of the thymus. link: http:/ww
44、w.ncbi.nlm.nih.gov/pubmed/15084623 Tumor recurrence and survival in patients treated for thymomas andthymic squamous cell carcinomas: a retrospective analysis. Strbel P1, Bauer A, Puppe B, Kraushaar T, Krein A, Toyka K, Gold R, Semik M, Kiefer R, Nix W, Schalke B,Mller-Hermelink HK, Marx A. Author i
45、nformation Abstract PURPOSE: Thymic epithelial tumors (TET) are rare epithelial neoplasms of the thymus with considerable histologic heterogeneity. This retrospective study focused on the correlation of WHO-defined TET histotypes with survival and tumor recurrence in a large cohort of patients recei
46、ving different modes of treatment. PATIENTS AND METHODS: Two hundred twenty-eight patients were followed for up to 21 years (median, 60 months; range, 1 to 252 months) after primary surgery. Forty-two patients received adjuvant radiotherapy (mean dose, 53 Gy), and 33 patients received adjuvant chemo
47、therapy. RESULTS: Seventy-six (88%) of 86 patients with WHO type A, AB, and B1 thymomas were treated by surgery alone, with three tumor relapses after 3 to 10 years (median, 3.4 years). Twelve of 67 patients with WHO type B2 and B3 thymomas in Masaoka stages I and II were treated by adjuvant radioth
48、erapy without evidence of tumor recurrence after 1 to 12 years (median, 4 years). Among 75 patients with B2 and B3 thymomas with incomplete resection or a tumor stage III or higher, the recurrence rate was 34% (n = 23) after 0.5 to 17 years (median, 5 years) in patients receiving adjuvant radiochemo
49、therapy, compared to 78% (seven of nine patients) in patients without adjuvant radiochemotherapy. Incomplete tumor resection was associated with a high recurrence rate (65%) and a poor prognosis (P .01). CONCLUSION: The long-term outcome of TET patients is related to tumor stage, WHO histotype, completeness of surgical removal, and type of treatment. Prospective trials are warranted to formally address the efficacy of adjuvant therapy in the treatment of localized and advanced malignant TETs. http:/www.ncbi.nlm.nih.gov/pubmed/12795160 Thymic carcinoma (mixed sm
